Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over yearAug 13Clinical readoutAscendis Pharma A/Snavepegritide
Ascendis Pharma Bone's Yorvipath gets labeling supplement approved by FDAAug 3Regulatory decisionAscendis Pharma A/Spalopegteriparatide
Ascendis Pharma registers Phase 3 trial of Yorvipath in adolescent hypoparathyroidismJul 16Trial updateAscendis Pharma A/Spalopegteriparatide
Sign inSign in